The Committee for Medicinal Products for Human Use (CHMP), part of the European Medicines Agency, has handed down a negative opinion on the approval of combination ipilimumab and nivolumab for the frontline treatment of advanced renal cell carcinoma. The main reason for this decision is the lack of a nivolumab monotherapy arm in the study. This decision currently leaves a treatment with up to 16 percent complete response rate in intermediate and poor risk disease groups unavailable to European
World Kidney Cancer Q&A Day is on 21 June 2018
Leading up to the second World Kidney Cancer Day, people all around the world will be asking questions and looking for answers to help raise global awareness of kidney cancer.
World Kidney Cancer Day provides the opportunity for patients, carers, their friends and supporters, health care professionals and local kidney cancer organisations, to come together to raise awareness and start to answer those questions that will make a difference to stemming
Note: The following summary was prepared for the benefit of patient organisations who focus on kidney cancer. While this summary has been medically reviewed, the information contained herein is based upon public data shared at this meeting and is not intended to be exhaustive. Patients should ask their physician about any information that pertains to their care.
The American Society of Clinical Oncology (ASCO) Conference in Chicago June 1-5 2018 brought together oncology professionals, patient
Note: The following summary was prepared by patient advocates for the benefit of patient organisations who focus on kidney cancer. While this summary has been medically reviewed, the information contained herein is based upon public data shared at this meeting and is not intended to be exhaustive. Patients should ask their physician about any information that pertains to their care.
Summary of Kidney Cancer Take-Home Messages from ESMO 2017
Over 24,000 people attended the ESMO (European Society of Medical Oncology) meeting in Madrid from September 8–12
The IKCC clinical trials database is provided as an information resource for kidney cancer patient organisations worldwide. The IKCC database is automatically updated daily and reviewed weekly. All trial information is sourced from and automatically updated according to www.clinicaltrials.gov according to a wide variety of search terms commonly used for kidney cancer.
Note: Patients should always check with their healthcare provider and their local patient organisation for additional trials that
Information presented on this website is intended to supplement, not replace, conversations between the patient and their healthcare team. The specific details about each patient’s total health situation and personal values need to be considered in making the final decisions about taking part in a clinical trial.
Information in the IKCC database is sourced from a recognized worldwide database: www.clinicaltrials.gov. It is possible that some trials in some countries may not be listed. Speak to